Publications - Julian R . Molina, M.D., Ph.D.

Back to Research Profile

1. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Allen Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non-Small-Cell Lung Cancer: NCCTG and SWOG Study N0426. J Clin Oncol 2009 Oct 19. [Epub ahead of print]
   View PubMed
2. Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Beleford D, Lai J, Roberts LR, Molina J, Kaufmann SH, Prendergast GC, Shridhar V. A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. Oncogene 2008 Dec 11; 27(58):7223-34. Epub 2008 Sep 22.
   View PubMed
3. Molina JR, Kaufmann SH, Reid JM, Rubin SD, Galvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res 2008 Dec 1; 14(23):7900-8.
   View PubMed
4. Ahmed AU, Schmidt RL, Park CH, Reed NR, Hesse SE, Thomas CF, Molina JR, Deschamps C, Yang P, Aubry MC, Tang AH. Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. J Natl Cancer Inst 2008 Nov 19; 100(22):1606-29. Epub 2008 Nov 11.
   View PubMed
5. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry MC. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 2008 Sep; 21(9):1168-75.
   View PubMed
6. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry MC. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 2008 Sep; 21(9):1168-75. Epub 2008 Jun 27.
   View PubMed
7. Mateen FJ, Jatoi A, Lineberry TW, Aranguren D, Creagan ET, Croghan GA, Jett JR, Marks RS, Molina JR, Richardson RL. Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report. Psychooncology 2008 Jul; 17(7):721-5.
   View PubMed
8. Molina JR. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 2008 Jul; 11(7):508-21.
   View PubMed
9. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008 May 1; 26(13):2139-46. Epub 2008 Apr 07.
   View PubMed
10. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008 May; 83(5):584-94.
    View PubMed
11. Diago T, Pulido JS, Molina JR, Collett LC, Link TP, Ryan EH Jr. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc 2008 Feb; 83(2):231-4.
    View PubMed
12. Molina JR, Quevedo JF, Furth AF, Richardson RL, Zincke H, Burch PA. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer 2007 Dec 1; 110(11):2434-40.
    View PubMed
13. Aubry MC, Heinrich MC, Molina J, Lewis JE, Yang P, Cassivi SD, Corless CL. Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. Cancer 2007 Dec 1; 110(11):2507-10.
    View PubMed
14. Molina JR, Quevedo JF, Furth AF, Richardson RL, Zincke H, Burch PA. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer 2007 Dec 1; 110(11):2434-40.
    View PubMed
15. Molina JR, Aubry MC, Lewis JE, Wampfler JA, Williams BA, Midthun DE, Yang P, Cassivi SD. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer 2007 Nov 15; 110(10):2253-9.
    View PubMed
16. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007 Oct 1; 13(19):5834-40.
    View PubMed
17. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase I Dose Escalation Study of the Anti Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors. Clin Cancer Res 2007 October 1; 13(19):5834-40.
    View PubMed
18. Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, Scheerer M, Roberts LR, Molina J, Shridhar V. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene 2007 Jul 26; 26(34):4969-78. Epub 2007 Feb 19.
    View PubMed
19. Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, Simantov R. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007 May 1; 13(9):2684-91.
    View PubMed
20. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest 2006 Oct; 130(4):1211-9.
    View PubMed
21. Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikcevich D. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. Am J Clin Oncol 2006 Jun; 29(3):246-51.
    View PubMed
22. Osborn NK, Zou H, Molina JR, Lesche R, Lewin J, Lofton-Day C, Klatt KK, Harrington JJ, Burgart LJ, Ahlquist DA. Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia. Clin Gastroenterol Hepatol 2006 Feb; 4(2):212-8.
    View PubMed
23. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol 2006 Jan; 1(1):7-9.
    View PubMed
24. Ward IM, Difilippantonio S, Minn K, Mueller MD, Molina JR, Yu XC, Frisk CS, Ried T, Nussenzweig A, Chen JJ. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol 2005 Nov; 25(22):10079-86.
    View PubMed
25. Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs 2005 Oct; 16(9):997-1002.
    View PubMed
26. Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ, Ahlquist DA. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005 Sept 10; 116(4):584-91.
    View PubMed
27. Giordano KF, Jatoi A, Adjei AA, Creagan ET, Croghan G, Frytak S, Jett JR, Marks R, Molina J, Okuno S, Richardson RL. Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. Lung Cancer 2005 Aug; 49(2):209-15.
    View PubMed
28. Zou HZ, Osborn NK, Harrington JJ, Klatt KK, Molina JR, Burgart LJ, Ahlquist DA. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005 Apr; 14(4):830-4.
    View PubMed
29. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST, Urrutia R, Billadeau DD. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005 Jan; 7(1):39-49.
    View PubMed
30. Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf 2005; 28(5):401-16.
    View PubMed
31. Sun Z, Yang P, Aubry MC, Kosari F, Endo C, Molina J, Vasmatzis G. Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung? Mol Cancer 2004 Dec 3; 3(1):35.
    View PubMed
32. Yang P, Sun Z, Aubry MC, Kosari F, Bamlet W, Endo C, Molina JR, Vasmatzis G. Study design considerations in clinical outcome research of lung cancer using microarray analysis. Lung Cancer 2004 Nov; 46(2):215-26.
    View PubMed
33. Visbal AL, Williams BA, Nichols FC III, Marks RS, Jett JR, Aubry MC, Edell ES, Wampfler JA, Molina JR, Yang P. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004 Jul; 78(1):209-15.
    View PubMed
34. Molina JR, Adjei AA. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clinical Lung Cancer 2003 Jul; 5(1):21-7.
    View PubMed
35. Molina JR, Rajkumar SV. Angiogenesis and multiple myeloma. Closing in on the gap. Haematologica 2003 Feb; 88(2):122-4.
    View PubMed
36. Dai Z, Wei-Guo Z, Morrison CD, Brena RM, Smiraglia DJ, Aparna R, Yue-Zhong W, Rush LJ, Ross P, Molina JR, Otterson GA, Plass C. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet 2003; 12(7):791-801.
    View PubMed
37. Boivin GP, Molina JR, Ormsby I, Stemmerman G, Doetschman T. Gastric lesions in TGFB-1 heterozygous mice. Lab Invest 1996; 74:513-8.
    View PubMed